BCR/ABL promotes dendritic cell-mediated natural killer cell activation

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6409-6417

  Terme, Magali ^a   Borg, Christophe ^a   Guilhot, François ^c   Masurier, Carole ^a,d   Flament, Caroline ^a   Wagner, Erwin F ^e   Caillat Zucman, Sophie ^f   Bernheim, Alain ^b   Turhan, Ali G ^a   Caignard, Anne ^a   Zitvogel, Laurence ^a  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d GÉNÉTHON   (France)

^e RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BINDING PROTEIN; IMATINIB; INTERFERON; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CELL ACTIVATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; FUSION GENE; GENE EXPRESSION REGULATION; GENE TRANSFER; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; MOUSE; MYELOPROLIFERATIVE DISORDER; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BONE MARROW CELLS; DENDRITIC CELLS; FEMALE; FUSION PROTEINS, BCR-ABL; GENE TRANSFER TECHNIQUES; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, CHRONIC; LIGANDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; RECEPTORS, IMMUNOLOGIC; TRANSLOCATION, GENETIC;

EID: 22244478990     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2675     Document Type: Article

References (43)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
2. Pierson BA, Miller JS. The role of autologous natural killer cells in chronic myelogenous leukemia. Leuk Lymphoma 1997;27;387-99.
3. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333-9.
4. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
5. Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 1996;87:2476-85.
6. Baron F, Turhan AG, Giron-Michel J, et al. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood 2002;99:2107-13.
7. Verfaillie C, Kay N, Miller W, McGlave P. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 1990;76:401-8.
8. Carayol G, Giron-Michel J, Azzarone B, et al. Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patients. Oncogene 2000;19:2758-66.
9. Nakajima H, Zhao R, Lund TC, et al. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J Immunol 2002;168:643-50.
10. Chiorean EG, Dylla SJ, Olsen K, Lenvik T, Soignier Y, Miller JS. BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs). Blood 2003;101:3527-33.
11. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-11.
12. Andrews DM, Scalzo AA, Yokoyama WM, Smyth MJ, Degli-Esposti MA. Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol 2003;4:175-81.
13. Valteau-Couanet D, Leboulaire C, Maincent K, et al. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 2002;100:2554-61.
14. Fernandez NC, Flament C, Crepineau F, Angevin E, Vivier E, Zitvogel L. Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur Cytokine Netw 2002;13:17-27.
15. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-33.
16. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002;195:335-41.
17. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKpSO receptor by activated NK cells. J Exp Med 2002;195:343-51.
18. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002;195:F9-14.
19. Eibl B, Ebner S, Duba C, et al. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 1997;20:215-23.
20. Dietz AB, Bulur PA, Erickson MR, et al. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells. J Hematother Stem Cell Res 2000;9:95-101.
21. Eisendle K, Lang A, Eibl B, et al. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br J Haematol 2003;120:63-73.
22. Smit WM, Rijnbeek M, van Bergen CA, et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol 1997;53:216-23.
23. Heinzinger M, Waller CF, von den Berg A, Rosenstiel A, Lange W. Generation of dendritic cells from patients with chronic myelogenous leukemia. Ann Hematol 1999;78:181-6.
24. Westermann J, Kopp J, Korner I, et al. Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia. Bone Marrow Transplant 2000;2S Suppl 2:S46-9.
25. Choudhury A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997;89:1133-42.
26. Mannering SI, McKenzie JL, Hart DN. Optimisation of the conditions for generating human DC initiated antigen specific T lymphocyte lines in vitro. J Immunol Methods 1998;219:69-83.
27. Nieda M, Nicol A, Kikuchi A, et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998;91:977-83.
28. Osman Y, Takahashi M, Zheng Z, et al. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 1999;13:166-74.
29. Muller L, Provenzani C, Faul C, Pawelec G. Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells. Br J Haematol 2001;112:740-8.
30. Dong R, Cwynarski K, Entwistle A, et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 2003;101:3560-7.
31. Wang C, Al-Omar HM, Radvanyi L, et al. Clonal heterogeneity of dendritic celis derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-α. Exp Hematol 1999;27:1176-84.
32. Passegue E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 2001;104:21-32.
33. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996;87:307-17.
34. Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-65.
35. Berthier R, Martinon-Ego C, Laharie AM, Marche PN. A two-step culture method starting with early growth factors permits enhanced production of functional dendritic cells from murine splenocytes. J Immunol Methods 2000;239:95-107.
36. Ahmed M, Dusanter-Fourt I, Bernard M, et al. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line. Oncogene 1998;16:489-96.
37. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998;92:3780-92.
38. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990;9:1069-78.
39. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002;100:1935-47.
40. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-96.
41. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-71.
42. Gabriele L, Borghi P, Rozera C, et al. IFN-α promotes the rapid differentiation of monocles from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 2004;103:980-7.
43. Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A. Cutting edge: murine dendritic cells require IL-15Rα to prime NK cells. J Immunol 2004;173:3594-8.